Data Extraction Template

Published You published about 1 year ago.

Save as Draft Publish

Item Settings

Editor

I want to start from scratch

H1

General information

Aa

Study ID

Aa

Title

Aa

Lead author contact details

Country in which the study conducted

1. –
   United States
2. –
   UK
3. –
   Canada
4. –
   Australia
5. –
   Other

Aa

Notes

H1

Characteristics of included studies

H2

Methods

Aa

Aim of study

Study design

1. –
   Randomised controlled trial
2. –
   Non-randomised experimental study
3. –
   Cohort study
4. –
   Cross sectional study
5. –
   Case control study
6. –
   Systematic review
7. –
   Qualitative research
8. –
   Prevalence study
9. –
   Case series
10. –
    Case report
11. –
    Diagnostic test accuracy study
12. –
    Clinical prediction rule
13. –

Economic evaluation

14. –

Text and opinion

15. –

Other

Aa

Start date

Aa

End date

Aa

Study funding sources

Aa

Possible conflicts of interest for study authors

H2

Participants

Aa

Population description

Aa

Inclusion criteria

Aa

Exclusion criteria

Method of recruitment of participants

1. –

Phone

2. –

Mail

3. –

Clinic patients

4. –
   Voluntary
5. –
   Other

Aa

Total number of participants

Type of Mole

1. –
   Complete Mole
2. –
   Partial Mole
3. –
   Invasive Mole
4. –
   Choriocarcinoma
5. –
   Placental Site Trophoblastic Tumor
6. –
   Epithelioid Trophoblastic Tumor
7. –
   Other

Time of Contraception Start

1. –
   Immediately following GTD treatment
2. –
   After beta-hCG normalization
3. –
   Other

Baseline Characteristics

Contraception

Beta-hCG Normalization

Post-molar GTN

Incident Pregnancies

Adverse Events

Preview

General information

Study ID

Title

Title of paper / abstract / report that data are extracted from

Lead author contact details

Country in which the study conducted

1. United States
2. UK
3. Canada
4. Australia
5. Other

Notes

Characteristics of included studies

Methods

Aim of study

Study design

1. Randomised controlled trial
2. Non-randomised experimental study
3. Cohort study
4. Cross sectional study
5. Case control study
6. Systematic review
7. Qualitative research
8. Prevalence study
9. Case series
10. Case report
11. Diagnostic test accuracy study
12. Clinical prediction rule
13. Economic evaluation
14. Text and opinion
15. Other

Start date

End date

Study funding sources

Possible conflicts of interest for study authors

Participants

Population description

Inclusion criteria

Exclusion criteria

Method of recruitment of participants

1. ○ Phone
2. ○ Mail
3. ○ Clinic patients
4. ○ Voluntary
5. ○ Other

Total number of participants

Type of Mole

1. ☐ Complete Mole
2. ☐ Partial Mole
3. ☐ Invasive Mole
4. ☐ Choriocarcinoma
5. ☐ Placental Site Trophoblastic Tumor
6. ☐ Epithelioid Trophoblastic Tumor
7. ☐ Other

Time of Contraception Start

1. ☐ Immediately following GTD treatment
2. ☐ After beta-hCG normalization
3. ☐ Other

Baseline Characteristics

	Contraception Type 1	Contraception Type 2	Total Population	Additional Notes
Contraception Type				
Age (mean)				
Gravidity (mean)				
Parity (mean)				

Contraception

	Combined oral contraceptive pills	Vaginal Ring	Patch	Progestin only pills	Copper IUD	Progestin IUD	DMPA	Implant	Barrier Methods	Other
Number of Participants on Method										
Length of Time on Method (Average)										

Beta-hCG Normalization

	Mean Time (in days)	SD
Combined oral contraceptive pills		
Vaginal Ring		
Patch		
Progestin only pills		
Copper IUD		
Progestin IUD		
DMPA		
Implant		
Barrier Methods		
Other		
None		

Post-molar GTN

	Number of Participants
Combined oral contraceptive pills	
Vaginal Ring	
Patch	
Progestin only pills	
Copper IUD	
Progestin IUD	
DMPA	
Implant	
Barrier Methods	
Other	
None	

Incident Pregnancies

	Number of Participants
Combined oral contraceptive pills	
Vaginal Ring	
Patch	
Progestin only pills	
Copper IUD	
Progestin IUD	
DMPA	
Implant	

	Number of Participants
Barrier Methods	
Other	
None	

Adverse Events

	Adverse Event Type 1	Number of Participants	Adverse Event Type 2	Number of Participants	Adverse Event Type 3	Number of Participants
Combined oral contraceptive pills						
Vaginal Ring						
Patch						
Progestin only pills						
Copper IUD						
Progestin IUD						
DMPA						
Implant						
Barrier Methods						
Other						
None						